← All trials
NCT04853836
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Oct 1, 2021
- First posted
- Apr 21, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PerugiaLead sponsor
- Humanitas UniversityCollaborator
- University of SassariCollaborator
- University of CataniaCollaborator
- University of PalermoCollaborator
- University of FlorenceCollaborator
- University of PerugiaReponsible party - principal investigator
- University of Naples Frederico IICollaborator
- Azienda Ospedaliera San Giovanni AddolorataCollaborator
- Marche Polytechnic UniversityCollaborator
- Istituto per la Sicurezza Sociale (ISS) della Repubblica di San MarinoCollaborator
- Ospedale Bufalini di Cesena, ItalyCollaborator
- Ospedale Universitario di Genova, ItalyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.